TY - JOUR

T1 - 2019 update to

T2 - Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

AU - Buse, John B.

AU - Wexler, Deborah J.

AU - Tsapas, Apostolos

AU - Rossing, Peter

AU - Mingrone, Geltrude

AU - Mathieu, Chantal

AU - D’Alessio, David A.

AU - Davies, Melanie J.

N1 - Correction: https://link.springer.com/article/10.1007%2Fs00125-020-05151-2

PY - 2020

Y1 - 2020

N2 - The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycaemia, based on important research findings from large cardiovascular outcomes trials published in 2019. Important changes include: (1) the decision to treat high-risk individuals with a glucagon-like-peptide 1 (GLP-1) receptor agonist or sodium–glucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse cardiovascular events (MACE), hospitalisation for heart failure (hHF), cardiovascular death or chronic kidney disease (CKD) progression should be considered independently of baseline HbA1c or individualised HbA1c target; (2) GLP-1 receptor agonists can also be considered in patients with type 2 diabetes without established cardiovascular disease (CVD) but with the presence of specific indicators of high risk; and (3) SGLT2 inhibitors are recommended in patients with type 2 diabetes and heart failure, particularly those with heart failure with reduced ejection fraction, to reduce hHF, MACE and CVD death, as well as in patients with type 2 diabetes with CKD (eGFR 30 to ≤60 ml min−1 [1.73 m]−2 or urinary albumin-to-creatinine ratio >30 mg/g, particularly >300 mg/g) to prevent the progression of CKD, hHF, MACE and cardiovascular death.

AB - The American Diabetes Association and the European Association for the Study of Diabetes have briefly updated their 2018 recommendations on management of hyperglycaemia, based on important research findings from large cardiovascular outcomes trials published in 2019. Important changes include: (1) the decision to treat high-risk individuals with a glucagon-like-peptide 1 (GLP-1) receptor agonist or sodium–glucose cotransporter 2 (SGLT2) inhibitor to reduce major adverse cardiovascular events (MACE), hospitalisation for heart failure (hHF), cardiovascular death or chronic kidney disease (CKD) progression should be considered independently of baseline HbA1c or individualised HbA1c target; (2) GLP-1 receptor agonists can also be considered in patients with type 2 diabetes without established cardiovascular disease (CVD) but with the presence of specific indicators of high risk; and (3) SGLT2 inhibitors are recommended in patients with type 2 diabetes and heart failure, particularly those with heart failure with reduced ejection fraction, to reduce hHF, MACE and CVD death, as well as in patients with type 2 diabetes with CKD (eGFR 30 to ≤60 ml min−1 [1.73 m]−2 or urinary albumin-to-creatinine ratio >30 mg/g, particularly >300 mg/g) to prevent the progression of CKD, hHF, MACE and cardiovascular death.

KW - Cardiovascular disease

KW - Chronic kidney disease

KW - Glucose-lowering therapy

KW - Guidelines

KW - Heart failure

KW - Hypoglycaemia

KW - Patient-centred care

KW - Type 2 diabetes mellitus

UR - https://link.springer.com/article/10.1007/s00125-020-05151-2

U2 - 10.1007/s00125-019-05039-w

DO - 10.1007/s00125-019-05039-w

M3 - Journal article

C2 - 31853556

AN - SCOPUS:85076591284

VL - 63

SP - 221

EP - 228

JO - Diabetologia

JF - Diabetologia

SN - 0012-186X

IS - 2

ER -